EN DE
Data-driven stock valuation

Abbisko Cayman Ltd (2256) fair value: what the stock is really worth

We calculate from audited financials what Abbisko Cayman Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · HK · Market cap HK$8.0B (≈ $1.0B) · ISIN KYG0028A1085

At a glance

AC Abbisko Cayman Ltd 2256 · HK
PriceHK$8.36
Fair ValueHK$1.49
Upside−82.2% ⚠
Quality72/100

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

A solid business, but trading 461% above our fair value of HK$1.49.

As of Aug 20, 2026, the fair value of Abbisko Cayman Ltd is HK$1.49 per share against a price of HK$8.36, so the fair value sits 82% below the price. A model estimate from reported figures, not an analyst target.

!Mixed Growth (revenue YoY +18.3 %/yr)
!Thin margins · 9.0% net margin
✓Low debt · generates free cash flow
!Mixed vs. peers (6/11)
!Narrow moat 31/100
!Evidence only low, so the estimate is less certain
!Weak on past: 11 out of 100
Evidence: Low Range HK$1.40 to HK$1.86

Fair value as of: Aug 20, 2026

From 24 valuation models · updated 22 days ago

Share price −26.2% over the past month.

Watch Abbisko Cayman Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits above even our optimistic bull case (HK$1.86). The favourable scenario is already priced in.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

HK$19.62 HK$2.17 Fair Value HK$1.49 Oct 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.

How to read this chart

59‑month range HK$2.17 – HK$19.62 · fair‑value band HK$1.40 – HK$1.86 · the HK$8.36 price screens above the HK$1.49 fair value. Dashed = 300-day average. As of Aug 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Abbisko Cayman Ltd (2256) currently trades at HK$8.36, while our model-based Fair Value estimate is HK$1.49, implying the stock looks roughly 460.9% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$3.49 per share, and 0 of the 24 models we run sit above the HK$8.36 price. Bear case: the Economic Profit group reads lowest at HK$1.25, and 24 of the 24 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Abbisko Cayman Ltd generated revenue of HK$612M at a net margin of 9.0%. It earns a return on equity of 2.9%. The balance sheet holds a net cash position of HK$446M. The stock trades on a trailing P/E of 112.3 (as of Jul 2, 2026). Fundamentals as of Aug 20, 2026

Scenario range: HK$1.40 (bear) to HK$1.86 (bull), the price of HK$8.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic. The share trades about 58% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −82%, 2256 screens richer than that median.

Fair Value models

Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (HK$0.3549 per share) are deliberately not added.

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$2.68 HK$3.57 HK$6.33 76
Growth DCF HK$2.59 HK$3.98 HK$6.21 75
EPV HK$1.22 HK$1.25 HK$1.27 74
All 24 models by family
DCF Models
FCF DCF HK$2.68 HK$3.57 HK$6.33 76
Owner Earnings HK$2.51 HK$4.29 HK$7.89 71
5Y Revenue Exit HK$1.79 HK$2.15 HK$2.89 72
5Y EBITDA Exit HK$2.05 HK$2.68 HK$3.91 73
5Y P/E Exit HK$2.43 HK$4.04 HK$6.21 67
10Y Revenue Exit HK$2.05 HK$2.84 HK$3.21 66
10Y EBITDA Exit HK$2.26 HK$3.40 HK$5.27 65
10Y P/E Exit HK$2.53 HK$4.19 HK$6.89 60
Earnings-Based
Graham-Dodd HK$0.5100 HK$3.56 HK$5.00 61
Lynch FV HK$1.84 HK$2.63 HK$3.42 59
PEG = 1.0 HK$1.84 HK$2.63 HK$3.42 55
EPV HK$1.22 HK$1.25 HK$1.27 74
Multiples
P/E Multiple HK$1.24 HK$1.65 HK$2.07 63
P/S Multiple HK$0.9600 HK$1.28 HK$1.60 58
P/B Multiple HK$0.9600 HK$1.28 HK$1.60 55
EV/EBIT HK$1.53 HK$1.69 HK$1.85 66
EV/EBITDA HK$1.77 HK$2.01 HK$2.26 67
EV/Revenue HK$1.39 HK$1.54 HK$1.69 54
Asset-Based
NCAV (Graham) HK$1.34 HK$1.80 HK$2.69 54
Growth DCF
Growth DCF HK$2.59 HK$3.98 HK$6.21 75
Rev-Margin DCF HK$1.85 HK$2.31 HK$3.28 71
Economic Profit
Residual Income HK$1.90 HK$1.83 HK$1.49 68
ROIC Compounder HK$1.22 HK$1.25 HK$1.27 70
Growth Earnings
Growth-Adj P/E HK$2.44 HK$3.49 HK$4.54 65

Widest divergence: Growth Earnings (HK$3.49) versus Economic Profit (HK$1.25). Highest evidence: FCF DCF (76).

Notify me when 2256 reaches fair value

Put 2256 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 112.3 as of Jul 2, 2026
P/S ratio 10.1 P/E × margin
EPS (TTM) HK$0.5100 price ÷ EPS = P/E 112.3
Net margin 9.0% FY2025
Return on equity 2.9% TTM
Return on assets (EBIT) −11.3% avg 5y
More key figures
Profitability
Operating margin 4.6% TTM
Growth
Revenue (TTM) HK$612M TTM
EPS growth (YoY) +59.4%
Balance sheet & cash flow
Free cash flow HK$73.8M FY2025
Net cash HK$446M FY2025

Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 72/100

Of which business quality 72 · Market factors (momentum, volatility) 16

Profitability 30
Margins and returns on capital today
Quality Growth 69
Are margins and returns improving?
Cashflow 68
Earnings quality: real cash, not paper profit
Fin. Strength 95
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 32
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 84
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union.

Full company description

Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer. In addition, the company develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors; ABSK112 for non-small cell lung and breast cancers; ABK3376 for non-small cell lung cancer; ABSK131 for solid tumors; ABSK141 for solid tumors; and ABSK051 for solid tumors, as well as ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors. Further, it is involved in the development of drugs in IND enabling stage, such as ABSK211, ABSK191, and ABSK192 for solid tumors, as well as P151 for cardiometabolic; and drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Additionally, the company provides advisory and management services. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Abbisko Cayman Ltd reported revenue of 596M CNY in FY2025 versus 22.7M CNY in FY2021, a compound +126.4%/yr. Reported net income was 53.8M CNY in FY2025.

Growth Quality 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$596M
Latest YoY
+18.3%
Avg. revenue growth/yr (6Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+131.9%
EBIT margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,495.8% (2019) → 4.6% (2025)
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Revenue +126.4%/yr
FY21 22.7M CNY
FY22 0 CNY
FY23 19.1M CNY
FY24 504M CNY
FY25 596M CNY
Net income
FY21 −1.8B CNY
FY22 −498M CNY
FY23 −432M CNY
FY24 28.3M CNY
FY25 53.8M CNY

2256 screens 461% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Abbisko Cayman Ltd · Fair Value
HK$1.49 −461%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Abbisko Cayman Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2256

Peer Group

Biotechnology · 635 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 72 · Top 25%
Fair Value upside −83% · Bottom 25%
Profitability
Return on equity (TTM) 3% · Above median
Return on assets 1% · Above median
Net margin (TTM) 9% · Top 25%
Operating margin (TTM) 5% · Above median

Valuation Multiples vs Biotechnology median · lower = cheaper

P/E (TTM) 112.3× · Priciest 25%
P/B 4.18× · Priciest 25%
P/S (TTM) 13.14× · Priciest 25%
P/FCF 13.9× · Pricier than median

What the price implies (reverse DCF)

The inverse question: what free-cash-flow growth must Abbisko Cayman Ltd deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.

Implied FCF growth, 10 years+25.3 % per year
Achieved revenue growth, 6 years+131.9 % p.a.
Sector median revenue growth+4.4 %
FCF yield on price1.38 %
Discount rate (WACC) in the models12.4 %

The price demands less growth than the company recently delivered: even a weaker business would justify the price. Ranking of the largest stocks →

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE0 · sector 0
PAST11 · sector 0
HEALTH100 · sector 98
DIVIDEND0 · sector 27

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,452,000 KRW 1,055,793 KRW −27%
CSL Limited CSL A$174.50 A$141.68 −19%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%

Compare Abbisko Cayman Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Abbisko Cayman Ltd (2256) overvalued or undervalued?
As of Aug 20, 2026, our model estimates a fair value of HK$1.49 versus a price of HK$8.36, about −82% upside (overvalued).
What is the fair value of 2256?
Our model-based fair value for Abbisko Cayman Ltd is HK$1.49 (as of Aug 20, 2026), built from audited fundamentals. The current price: HK$8.36.
What is the quality score of 2256?
Abbisko Cayman Ltd has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Abbisko Cayman Ltd (2256)?
Our model-based price target is the fair value of HK$1.49 (as of Aug 20, 2026) from 24 valuation models. Cautious scenario HK$1.40, optimistic scenario HK$1.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Abbisko Cayman Ltd stock forecast for 2026?
Our models put fair value at HK$1.49, about −82% upside versus a price of HK$8.36 (overvalued). Cautious scenario HK$1.40, optimistic scenario HK$1.86. The calculation is refreshed regularly with new filings.
What is the revenue of Abbisko Cayman Ltd (2256)?
Abbisko Cayman Ltd reported trailing-twelve-month revenue of about HK$612M (latest available figure, as of Aug 20, 2026).
What is the net profit margin of 2256?
The net profit margin of Abbisko Cayman Ltd is about 9.0%, meaning it keeps roughly 9.0% of revenue as net income. Based on the latest reported figures.
What growth is priced into Abbisko Cayman Ltd (2256)?
For today's price to be fair in a discounted-cash-flow model, Abbisko Cayman Ltd would have to grow free cash flow by +25.3 % per year for ten years (discount rate 12.4 %, then 2 % perpetual growth). Over the last 6 years revenue grew +131.9 % per year. As of Aug 20, 2026.
What discount rate (WACC) does the fair value of 2256 use?
Our models discount Abbisko Cayman Ltd at 12.4 %: a base by market capitalisation (small), damped by beta 1.21, country premium for Hong Kong. The same rate applies in all 26 models.
What is the intrinsic value of Abbisko Cayman Ltd (2256)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Abbisko Cayman Ltd it is HK$1.49 per share (as of Aug 20, 2026), against a price of HK$8.36. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Abbisko Cayman Ltd stock overvalued or undervalued in 2026?
As of Aug 20, 2026, 2256 trades above its calculated fair value: price HK$8.36, fair value HK$1.49, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2256?
No. The price is what the market pays today (HK$8.36); the fair value is what the company's own numbers justify (HK$1.49). For Abbisko Cayman Ltd the two are HK$6.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Abbisko Cayman Ltd worth?
The market values Abbisko Cayman Ltd at about HK$8.0B (market capitalisation, as of Aug 20, 2026). Per share that is HK$8.36; our models calculate a fair value of HK$1.49 per share.
What do the bullish and bearish scenarios say about 2256?
Our models span a range for Abbisko Cayman Ltd: cautious scenario HK$1.40, base HK$1.49, optimistic HK$1.86 per share (as of Aug 20, 2026, price HK$8.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2256?
Abbisko Cayman Ltd trades at a price-to-earnings ratio of 112.3 (as of Aug 20, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.49 is built from several models across several years. Other multiples: P/B 4.2, P/S 13.1.
How solid is the balance sheet of Abbisko Cayman Ltd (2256)?
Balance-sheet figures for Abbisko Cayman Ltd (as of Aug 20, 2026): return on equity 2.9%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 2256 from its 52-week high?
Abbisko Cayman Ltd trades at HK$8.36, about 58% below its 52-week high of HK$19.78 (as of Aug 20, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.49 is for.
Which stocks are comparable to Abbisko Cayman Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Abbisko Cayman Ltd stock attractive at the current price?
The data as of Aug 20, 2026: price HK$8.36, calculated fair value HK$1.49 (−82%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2256 calculated?
We run Abbisko Cayman Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.49, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. Abbisko Cayman Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed

Watch Abbisko Cayman Ltd in the live analysis

One click puts Abbisko Cayman Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.